OncoCyte Corporation (OCX) Q4 Sales Increase

OncoCyte Corporation (OCX) (OCX) revealed Loss for fourth quarter of -$33.51 million

The company's bottom line came in at -$33.51 million, or -$1.93 per share. This compares with -$15.99 million, or -$1.96 per share, last year.

The company's revenue for the period rose 373.2% to $1.486 million from $0.314 million last year.

OncoCyte Corporation (OCX) earnings at a glance (GAAP) :

-Earnings: -$33.51 Mln. vs. -$15.99 Mln. last year.
-EPS: -$1.93 vs. -$1.96 last year.
-Revenue: $1.486 Mln vs. $0.314 Mln last year.

by RTTNews Staff Writer

For comments and feedback: editorial@rttnews.com